Skip to content
ApprovedFDA approved

Tesamorelin

Approved medicine for HIV-related lipodystrophy that reduces the belly fat around internal organs.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Tesamorelin vial

DETAILED OVERVIEW

What is Tesamorelin?

Tesamorelin (Egrifta) is an approved medicine. The US drug regulator (the FDA) approved it in 2010 for lipodystrophy linked to HIV infection (an abnormal distribution of body fat), to reduce the belly fat that builds up around the internal organs (visceral fat). It is a lab-made, stabilised version of the hormone that triggers the release of growth hormone.

It stimulates the pituitary gland's natural release of growth hormone, while the level of a related growth factor (IGF-1) stays within the normal range. In trials, the fat around the internal organs fell significantly, while fat under the skin and muscle mass were preserved or improved. In a study lasting a year, the fat loss was sustained and the medicine was well tolerated.

Type

Modified version of growth hormone-releasing hormone (GHRH)

Structure

trans-3-hexenoyl-hGRF(1-44)NH₂

Molecular weight

~5135 Da

Target area

Visceral fat (HIV lipodystr.)

Storage

2–8°C (reconstituted)

Stability

~7 days (per label)

Growth hormone release

The peptide acts on pituitary GHRH or GHS receptors, producing a physiological, pulsatile GH release, unlike synthetic rHGH, which keeps levels flat and leads to desensitization. IGF-1 rises into the upper-normal range, driving recovery, muscle protein synthesis, lipolysis and skin quality. Deep-sleep phases lengthen; collagen and bone-matrix synthesis activate. The effect is reversible and does not suppress the endogenous GH axis.

Metabolic support

Glucose and lipid metabolism shift favorably: insulin sensitivity improves, glycemic swings and HbA1c drop, while LDL and triglycerides normalize. Body composition refines, fat mass decreases, lean mass is preserved or grows. Appetite is regulated both centrally and peripherally (GLP-1 / GIP / glucagon pathways), so caloric intake settles into a sustainable range without constant willpower. Energy expenditure and thermogenesis rise modestly.

Data console

Lab data

ClassificationModified version of growth hormone-releasing hormone (GHRH)
Structuretrans-3-hexenoyl-hGRF(1-44)NH₂
Molecular weight~5135 Da
Target areaVisceral fat (HIV lipodystr.)
Storage2–8°C (reconstituted)
Stability~7 days (per label)

Research indications

Investigated uses and mechanisms

Growth hormone release

Mimics physiological pulsatile GH secretion; IGF-1 rise.

Recovery & body comp

Muscle mass gain, fat reduction, post-workout recovery.

Sleep quality

Deep-sleep (N3) phases lengthen.

Reconstitution

How to prepare, step by step

Important

Sterile technique required. Use bacteriostatic water (BAC) only. Never distilled or tap water.

  1. 01

    Remove the vial and bacteriostatic water (BAC) from refrigeration; let them reach room temp for 5 minutes.

  2. 02

    Wipe both vial stoppers with an alcohol swab.

  3. 03

    Draw 2 ml of BAC water into a sterile syringe (typical for the 2 mg vial).

  4. 04

    Inject slowly down the side of the vial, do NOT spray directly onto the peptide powder.

  5. 05

    Swirl gently in a circular motion until dissolved (~30 s), do not shake.

  6. 06

    Wait for the solution to become clear. If sediment or discoloration appears, discard it.

  7. 07

    Label the vial with reconstitution date and concentration.

  8. 08

    Store at 2–8 °C, protected from light. Inspect visually before each use.

Quality indicators

How to recognize a pure peptide

Purity markers

4
  • White / off-white powder

    Typical appearance of sterile lyophilized peptide.

  • Comes with COA (Certificate of Analysis)

    Independent lab analysis, ≥98% purity.

  • Intact, sealed vial

    Rubber stopper + aluminum crimp intact, ensuring sterility.

  • Dissolves clear

    Clear solution after reconstitution, no sediment.

Use caution

1
  • Storage temperature

    Extended room-temp exposure may reduce potency.

Do not use

2
  • Discoloration / sediment

    Yellow, cloudy or particulate solution, indicates degradation, do not use.

  • Damaged packaging

    Cracked vial or loose cap, sterility compromised, discard.

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Injection-site redness, itching
  • Water retention, mild edema
  • Wrist / joint stiffness (carpal-tunnel-like)
  • Transient blood-glucose increase
  • Mild prolactin / cortisol increase (some peptides)

Contraindications · 5

  • Pregnancy and breastfeeding
  • Active malignancy
  • Known allergy to the peptide or its components
  • Severe hepatic or renal impairment (medical consultation required)
  • Age under 18

Related Peptides

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Tesamorelin?

Reach out to an advisor on Telegram. We can help you find the right peptide.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.